BETA vs MOLBIO: Stock Comparison
MOLBIO DIAGNOSTICS is the larger company by market capitalisation. BETA DRUGS shows a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BETA leads 4; MOLBIO leads 0 of 7
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | BETA | MOLBIO |
|---|---|---|
| Live Price | ₹1,805.9 | ₹1,339.3 |
| Day Change | -1.89% | -4.57% |
| Volume | 15,899 | 9.88 L |
| 52-Week High | ₹2,807.9 | ₹1,686.8 |
| 52-Week Low | ₹990.1 | ₹926.35 |
| Distance from 52W High | -35.69% | -20.6% |
Valuation
| Metric | BETA | MOLBIO |
|---|---|---|
| Market Cap | ₹2,011 Cr | ₹15,523 Cr |
| P/E Ratio | 35.56x | — |
| P/B Ratio | 4.19x | — |
| EPS | ₹18 | ₹5.1 |
| Book Value | ₹220.09 | — |
| Dividend Yield | 0% | 0% |
Growth
| Metric | BETA | MOLBIO |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 9.51% | 0% |
| Qtr Profit Growth | 16.98% | 0% |
Profitability & Leverage
| Metric | BETA | MOLBIO |
|---|---|---|
| ROE | 14.79% | — |
| ROCE | 18.03% | — |
| Net Margin | 10.78% | 0% |
| Operating Margin | 16.79% | — |
| Debt to Equity | 0.6x | — |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | BETA | MOLBIO |
|---|---|---|
| Promoter Holding | 58.91%▼ 0.19 pp | 41.29% |
| FII Holding | 1.37%▲ 0.35 pp | 1.59%▲ 0.08 pp |
| DII Holding | 6.45%▲ 0.22 pp | 19.08%▲ 2.71 pp |
| Public Holding | 33.27%▼ 0.38 pp | 38.03%▼ 2.79 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BETA DRUGS and MOLBIO DIAGNOSTICS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.